Pharmaceutical Technology

OCTOBER 7, 2022

A bi-specific antibody, SZN-413 acts on Fzd4-mediated Wnt signalling. Surrozen CEO Craig Parker said: “Surrozen looks forward to the new partnership with Boehringer Ingelheim and to having our teams and scientists work to advance the potential opportunities for our Fzd4-targeted Wnt agonist programme. “We

Development 147

Development Genetics Sales Antibody 147

XTalks

JANUARY 11, 2023

The new subvariant has also been dubbed “Kraken” by some scientists. on the horizon as scientists say the virus appears to be rapidly evolving , mutating faster than most viruses. likely emerged through the genetic recombination of the Omicron BA.2.10.1 and its descendants. There could be newer versions of XBB.1.5

Scientist 98

Scientist Vaccination Vaccine Genetics 98

The Pharma Data

AUGUST 28, 2020

While we know for sure that children can catch the virus, Prof Viner says data from antibody blood tests suggest they may be less susceptible to catching it than adults – particularly children under the age of 12. Do they pass it on to others? ” So can we draw a conclusion?

Scientist 52

Scientist Genetics Antibody Development 52

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).

Antibody 52

Antibody Trials Production Clinical Trials 52

Pharmaceutical Technology

JULY 5, 2022

On leaving the liver cells, the virus hijacks bits of cell membrane and conceals itself from antibodies that would have isolated the virus before it travelled far through the bloodstream. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genome Genomics 130

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. In glioblastoma, as with many other highly recurrent cancers, tumour cells that escape treatment develop multiple genetic adaptations that allow them to proliferate.

Development 64

Development Research Drugs Antibody 64

The Pharma Data

DECEMBER 16, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics FDA Approval Antibody Medicine 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

MARCH 22, 2021

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days. The combination of casirivimab and imdevimab is the only monoclonal antibody treatment to retain potency against key emerging variants, based on the recently updated EUA guidance from the U.S.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 9, 2023

DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: What kind of T-cell response can we expect from the MHC-targeting antibody fragment-based approach?

Antibody 64

Antibody Protein Development Engineer 64

The Pharma Data

JANUARY 19, 2021

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics FDA Approval Antibody Medicine 52

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

The Pharma Data

NOVEMBER 30, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics FDA Approval Antibody Medicine 52

The Pharma Data

OCTOBER 27, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics FDA Approval Antibody Medicine 52

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. VOC 202012/01 has an unusually high number of genetic changes however, with 10 mutations affecting the spike protein. lineage or VOC 202012/01.

Vaccination 98

Vaccination Vaccine Antibody Protein 98

Drug Discovery World

MARCH 24, 2023

Our SpyVector technology, developed by our Principal Scientist Dr Matthew Dicks and his team, has the potential to generate more broadly protective coronavirus vaccines.” The post Developing next generation pan-SARS-CoV-2 vaccines appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Development Genetics 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. About REGN-COV2 REGN-COV2 was designed specifically by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron will distribute REGN-COV2 in the U.S.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

Scienmag

FEBRUARY 22, 2021

Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. ” But how do these antibodies function within the tumor? Using innovative in vivo imaging approaches, scientists […]. Using innovative in vivo imaging approaches, scientists […].

In-Vivo 41

In-Vivo Antibody Scientist Allergies 41

The Pharma Data

DECEMBER 5, 2020

NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Antibody 40

Antibody Production Trials Medicine 40

Drug Discovery World

DECEMBER 14, 2023

In addition, Glasgow is an attractive location to the brightest and best scientists from all over the world.  Its researchers represent some of the best scientists from around the world who have come together to work towards better outcomes for patients today and in the future.”

Drugs 75

Drugs Life Science Research Scientist 75

Drug Discovery World

AUGUST 28, 2023

DS: What role does genetics play in autophagy? Could therapies like these treat rare genetic conditions? PH : Genetics plays an enormous role. In fact, some variants of Parkinson’s and ALS are genetic in origin. Could it be possible to prevent genetic diseases? DS: What’s next for the company’s pipeline?

Genetics 52

Genetics Protein Genetic Disease Clinical Trials 52

XTalks

FEBRUARY 24, 2023

Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that works by targeting the protein CD20 on the surface of B cells and CD3 on the surface of T cells. Dr. Laport: Lunsumio (mosunetuzumab-axgb) is the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA.

FDA Approval 52

FDA Approval Drugs Antibody Medicine 52

Drug Discovery World

JULY 26, 2022

The talk will cover the technology behind the vaccine and the mechanisms of antibody and T cell immune responses triggered by the Covid-19 mRNA vaccine. . The lecture is one of a series of named lectures, organised by the LMB and given by eminent scientists from around the world. . Lecture abstract: .

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

The Pharma Data

MAY 31, 2022

A bout Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. There are approximately 75,000 people in the U.S. who are unable to control their disease with systemic therapy and are most in need of a treatment option.

Genetics 52

Genetics Antibody Medicine Trials 52

pharmaphorum

AUGUST 13, 2020

The FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that dramatically raises the risk of heart disease. There’s no data showing that the drug can reduce progression to heart disease yet, but it’s widely believed that cutting blood lipids can reduce that risk.

Drugs 52

Drugs Antibody Sales Cardiology 52

Drug Discovery World

MAY 25, 2023

Using complex models of cancer for preclinical testing After a coffee break, Prof Sansom was back behind the podium talking about the MRC National Mouse Genetics Network. Advances like genetically engineered mouse models (GEMMs), patient-derived xenografts (PDXs) and organoids are allowing the integration of mouse models with human cohorts.

Research 52

Research Drugs In-Vitro Insulin 52

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Production 52

Production Antibody Manufacturing Trials 52

The Pharma Data

MARCH 4, 2021

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. Detailed results from this Phase 3 trial will be published later this year. Source link:[link].

Genetics 52

Genetics Medicine Antibody Trials 52

pharmaphorum

DECEMBER 21, 2020

As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein. The body produces antibodies against the protein, which neutralise the virus in the event of an infection.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

The Pharma Data

OCTOBER 18, 2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. “We found that these individuals developed antibody responses that neutralized a common cold coronavirus, HCoV-OC43,” Penaloza-MacMaster said.

Vaccination 40

Vaccination Vaccine Immune Response Antibody 40

The Pharma Data

MARCH 13, 2022

assistant professor of medicine at the Johns Hopkins University School of Medicine and staff scientist at NIAID. assistant professor of medicine at the Johns Hopkins University School of Medicine and staff scientist at NIAID. population.

Immune Response 52

Immune Response Protein Medicine Genetics 52

The Pharma Data

FEBRUARY 19, 2022

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. About Dupixent. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Genetics 40

Genetics Antibody Trials Medicine 40

The Pharma Data

FEBRUARY 13, 2022

About Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. In 2016, the FDA granted Breakthrough Therapy designation for Dupixent for the treatment of severe atopic dermatitis (in children aged 6 months to 11 years).

Medicine 40

Medicine Genetics Antibody Allergies 40

pharmaphorum

JANUARY 20, 2021

The variant that originated in South Africa carries a mutation in the Spike protein that has been shown to reduce antibody recognition and could therefore affect efficacy of new vaccines. The partnership aims to develop a vaccine consisting of regions of genetical material from each coronavirus that causes an immune reaction.

Vaccination 52

Vaccination Vaccine Protein RNA 52